<SEC-DOCUMENT>0001567619-20-016247.txt : 20200901
<SEC-HEADER>0001567619-20-016247.hdr.sgml : 20200901
<ACCEPTANCE-DATETIME>20200901173150
ACCESSION NUMBER:		0001567619-20-016247
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200901
FILED AS OF DATE:		20200901
DATE AS OF CHANGE:		20200901

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Innoviva, Inc.
		CENTRAL INDEX KEY:			0001080014
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38670
		FILM NUMBER:		201155203

	BUSINESS ADDRESS:	
		STREET 1:		2000 SIERRA POINT PARKWAY
		STREET 2:		SUITE 500
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		6502389600

	MAIL ADDRESS:	
		STREET 1:		2000 SIERRA POINT PARKWAY
		STREET 2:		SUITE 500
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER NAME:	
		FORMER CONFORMED NAME:	THERAVANCE INC
		DATE OF NAME CHANGE:	20020207

	FORMER NAME:	
		FORMER CONFORMED NAME:	ADVANCED MEDICINE INC
		DATE OF NAME CHANGE:	20000302

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entasis Therapeutics Holdings Inc.
		CENTRAL INDEX KEY:			0001724344
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824592913
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		(781) 810-0120

	MAIL ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Entasis Therapeutics Ltd
		DATE OF NAME CHANGE:	20171204
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc1.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2020-09-01</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001724344</issuerCik>
        <issuerName>Entasis Therapeutics Holdings Inc.</issuerName>
        <issuerTradingSymbol>ETTX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001080014</rptOwnerCik>
            <rptOwnerName>Innoviva, Inc.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>1350 OLD BAYSHORE HIGHWAY SUITE 400</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>BURLINGAME</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94010</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2020-09-01</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>4672897</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>2.675</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>18672897</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Warrants to Purchase Common Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.675</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2020-09-01</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>4672897</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>2.675</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2020-09-01</value>
            </exerciseDate>
            <expirationDate>
                <value>2025-09-01</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>4672897</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>18672897</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">See Exhibit 99.1</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>INNOVIVA, INC.; By: /s/ Pavel Raifeld; Chief Executive Officer</signatureName>
        <signatureDate>2020-09-01</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>i37090993.htm
<DESCRIPTION>EXPLANATION OF RESPONSES
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: asdf
         Document created using EDGARfilings PROfile 7.0.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center;">Explanation of Responses</div>
    <div><br>
    </div>
    <div>
      <div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z06d234ae900742ff9e6e3c8b50fc13cf" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">(1)</td>
              <td style="width: auto; vertical-align: top;">
                <div>As reflected in the Amendment No. 3 to Schedule 13D filed by Innoviva, Inc. (the &#8220;<font style="font-style: italic;">Reporting Person</font>&#8221;) with the U.S. Securities and Exchange Commission on September 1, 2020 (the &#8220;<font style="font-style: italic;">Schedule 13D/A</font>&#8221;), in connection the closing that occurred on September 1, 2020 pursuant to a securities purchase agreement, dated as of August 27, 2020 (the &#8220;<font style="font-style: italic;">Purchase
                    Agreement</font>&#8221; and, such closing, the &#8220;<font style="font-style: italic;">Closing</font>&#8221;), by and among Entasis Therapeutics Holdings Inc. (the &#8220;<font style="font-style: italic;">Issuer</font>&#8221;) and the purchasers named therein,
                  including the Reporting Person, the Reporting Person acquired 4,672,897 shares of common stock of the Issuer (&#8220;<font style="font-style: italic;">Shares</font>&#8221;) and warrants to purchase an additional 4,672,897 Shares (&#8220;<font style="font-style: italic;">Warrants</font>&#8221;) as set forth in this Form 4. As a result of the Closing, the Reporting Person beneficially owns 37,345,794 Shares.&#160; The Schedule 13D/A filed by the Reporting Person is incorporated by
                  reference in this Form 4; any description herein of the Schedule 13D/A is qualified in its entirety by reference to the Schedule 13D/A so filed by the Reporting Person.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
